Interim Safety Results of Amlitelimab (anti-OX40 Ligand Antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2 3 Ongoing Open-Label Study. J of Skin 2025, 9 (6), s602. https://doi.org/10.25251/mq5bgn88.